CLINICAL TRIALS PROFILE FOR MICARDIS

« Back to Dashboard

All Clinical Trials for MICARDIS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00034840 ↗	Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose	Completed	Bayer	Phase 4	2001-10-01	The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
NCT00034840 ↗	Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose	Completed	GlaxoSmithKline	Phase 4	2001-10-01	The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
NCT00034840 ↗	Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose	Completed	Boehringer Ingelheim	Phase 4	2001-10-01	The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.

Clinical Trial Conditions for MICARDIS

Condition Name

Condition Name for MICARDIS
Intervention	Trials
Hypertension	53
Healthy	3
Diabetic Nephropathies	2

Condition MeSH

Condition MeSH for MICARDIS
Intervention	Trials
Hypertension	50
Essential Hypertension	6
Kidney Diseases	3

Clinical Trial Locations for MICARDIS

Trials by Country

Trials by Country for MICARDIS
Location	Trials
United States	271
Canada	45
Korea, Republic of	9
Australia	7
France	6

Trials by US State

Trials by US State for MICARDIS
Location	Trials
California	12
Illinois	11
Texas	10
Georgia	10
Pennsylvania	9

Clinical Trial Progress for MICARDIS

Clinical Trial Phase

Clinical Trial Phase for MICARDIS
Clinical Trial Phase	Trials
Phase 4	18
Phase 3	12
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for MICARDIS
Clinical Trial Phase	Trials
Completed	61
Recruiting	7
Active, not recruiting	2

Clinical Trial Sponsors for MICARDIS

Sponsor Name

Sponsor Name for MICARDIS
Sponsor	Trials
Boehringer Ingelheim	52
Bayer	3
HK inno.N Corporation	2

Sponsor Type

Sponsor Type for MICARDIS
Sponsor	Trials
Industry	66
Other	33
NIH	1